What is LTGO's market cap?

$895.70M, based on the Nov 2 close of $13.51.

How much of LTGO is sold short?

785.9K shares, 1.6% of float, as of Oct 15, 2026.

What sector is LTGO in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · LTGOHealthcarePharmaceuticals

Latigo Biotherapeutics, Inc. Common Stock (LTGO)

$13.51−3.15%

Close Nov 2, 2026 · split-adjusted

Oct 30, 2026$13.95▼ 37.02% in range

Sep 11, 2026Low $13.95 · High $23.93Oct 30, 2026

What changed · written from our data

As of Nov 2, 2026

Latigo Biotherapeutics closed at $13.51 on Nov 2, down 3.15%, within 0.0% of its lowest close since Sep 11. Volume of 290.1K shares was 1.23× its 20-day average (close to normal).

Split-adjusted performance: -15.0% over one month.

Short interest was 785.9K shares at the Oct 15 settlement, down 5.6% from the prior report (1.6% of float, 2.5 days to cover).

Market cap$895.7M66.3M shares

Revenue · quarter——

Diluted EPS——

P/E · TTM—

Net margin—

Dividend yieldNone

Range since Sep 1113.51 – 23.93−43.5% from high

Volume290.1K1.23× 20-day avg

Volatility · 60d—Annualised

Short % of float1.6%2.5 days to cover

Net cash—

Next earnings—Not scheduled

Split-adjusted performance

1W −11.5%1M −15.0%3M —6M —YTD —1Y —3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum—

Revenue growth—

Net margin—

Value (low P/E)—

Size70

Industry medians: 6-month return −25.1%, revenue growth +6.4%, net margin −36.2%, P/E 15.8×.

Short interest

Details →

Shares short785.9K−5.6% vs prior

Days to cover2.5Settled Oct 15

% of float1.6%

Short vol. 10d48.0%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
LTGOLatigo Biotherapeutics	$13.51	−3.15%	—	—	—	—	$895.7M
OBXObsidian Therapeutics	$14.43	−2.43%	—	—	—	—	$891.4M	Compare
JBIOJade Biosciences	$13.93	−0.92%	−43.2%	—	—	—	$885.9M	Compare
KURAKura Oncology	$9.79	−4.58%	+5.8%	+36.5%	−327.3%	—	$870.9M	Compare
ANROAlto Neuroscience	$22.19	−1.81%	−11.9%	—	—	—	$870.8M	Compare
ORICOric Pharmaceuticals	$9.07	−1.84%	−5.8%	—	—	—	$940.1M	Compare
RIGLRigel Pharmaceuticals Inc. (New)	$50.53	−1.52%	+71.1%	−22.6%	22.0%	2.9	$943.9M	Compare
ALMSAlumis	$6.38	−5.20%	−74.7%	−37.7%	−8557.2%	—	$825.8M	Compare
SVRASavara	$4.73	−1.87%	−10.8%	—	—	—	$971.8M	Compare

News about Latigo Biotherapeutics

All news →

No recent articles focused on Latigo Biotherapeutics.

Quick answers

What does Latigo Biotherapeutics do?: Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain.
What is LTGO's market cap?: $895.70M, based on the Nov 2 close of $13.51.
How much of LTGO is sold short?: 785.9K shares, 1.6% of float, as of Oct 15, 2026.
What sector is LTGO in?: Healthcare, in the Pharmaceuticals industry.

About Latigo Biotherapeutics

Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.

HQ: Thousand Oaks, CAListed Aug 7, 2026latigobio.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology